Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

CRISPR-based microbial gene therapy delivers promise

2
SHARES

A microbial gene therapy can “eliminate antibiotic-resistant E. coli strains in the gut”, according to first-in-human study interim results.

CRISPR-based microbial gene therapy delivers promise

The novel CRISPR-Cas therapeutic selectively targets antibiotic-resistant E. coli which can cause life-threatening bloodstream infections”

Positive interim results from a Phase I trial have demonstrated that the first CRISPR-armed phage microbial gene therapy can reduce Escherichia coli (E. coli) levels in the GI tract.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

“With the combined killing effects of bacteriophages and CRISPR-Cas technology, SNIPR001 has demonstrated the ability to target and eliminate antibiotic-resistant E. coli strains in the gut,” Dr Christian Grøndahl, CEO and co-founder of SNIPR Biome commented.

The novel CRISPR-Cas therapeutic selectively targets antibiotic-resistant E. coli which can cause life-threatening bloodstream infections in vulnerable haematological cancer patients. It has potential to prevent these infections in over 35,000 cancer patients annually across Europe and the US, according to the researchers.

This innovative treatment provides “a safe alternative to traditional treatments that do not work against antibiotic-resistant strains, while sparing the rest of the gut microbiome,” Dr Grøndahl stated.

The results are a “significant milestone” in efforts to overcome antimicrobial resistance (AMR), according to Dr Grøndahl.

What is SNIPR001?

SNIPR001 is a combination of four CRISPR-armed phages that selectively target and eliminate E. coli that are resistant to fluoroquinolone. It can be used alone or in combination with fluoroquinolone as a decolonisation strategy.

Phase I study of the microbial gene therapy

In the Phase I study, 36 healthy adults were evaluated across three dose levels of SNIPR001. They were dosed orally over seven days. Those who received the gene therapy experienced only mild to moderate side effects and no withdrawals. Twelve of the participants received a placebo treatment.

Future developments

Phase I study results also support development of an intravenously administered version of SNIPR001. Clinical investigations for this therapy are being planned, noted SNIPR Biome.

Future studies are needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk cancer patients.

The pivotal research leading to the design of SNIPR001 has been published in Nature Biotechnology.

Global research consortium to help address antimicrobial resistance

Share via
Share via